As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ERROR 2

Yes! I want to get the latest chemistry news from C&EN in my inbox every week.

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

Thermo Fisher Scientific will expand its viral vector services with the construction of a facility in Plainville, Massachusetts. The $180 million project will more than double Thermo Fisher’s capacity to serve developers of gene therapies and vaccines. The company expanded similar operations last year in Alachua, Florida. It also has viral vector operations in Lexington and Cambridge, Massachusetts. Thermo Fisher expects the 26,900 m2 facility in Plainville to be completed in 2022, adding more than 200 jobs.